With several potential disease-modifying treatments in development for Huntington's disease, including mutant and total huntingtin-lowering approaches, identifying the optimum time to treat and suitable biomarkers for trials in early preHD is of timely importance. The gene discussed is HTT; the disease is juvenile Huntington disease.